Literature DB >> 18663754

Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF.

Angelo Carbone1, Laura Bernardini, Francesco Valenzano, Irene Bottillo, Clara De Simone, Rodolfo Capizzi, Anna Capalbo, Francesca Romano, Antonio Novelli, Bruno Dallapiccola, Pierluigi Amerio.   

Abstract

The etiology of mycosis fungoides (MF), the most frequent form of cutaneous T cell lymphoma (CTCL), is poorly understood. No specific genetic aberration has been detected, especially in early-stage disease, possibly due to the clinical and histological heterogeneity of patient series and to the different sources of malignant cells (skin, blood, or lymph node) included in most studies. Frozen skin biopsies from 16 patients with early-stage MF were studied using array-based comparative genomic hybridization. A DNA pool from healthy donors was used as the reference. Results demonstrated recurrent loss of 19, 7p22.1-p22.3, 7q11.1-q11.23, 9q34.12, 12q24.31, and 16q22.3-q23.1, and gain of 8q22.3-q23.1 and 21q22.12. The 12q24.31 region was recurrently deleted in 7/16 patients. Real-time PCR investigation for deletion of genes BCL7A, SMAC/DIABLO, and RHOF-three tumor suppressor genes with a putative role in hematological malignancies-demonstrated that they were deleted in 9, 10, and 13 cases, respectively. The identified genomic alterations and individual genes could yield important insights into the early steps of MF pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663754     DOI: 10.1002/gcc.20601

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

Review 1.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

2.  The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).

Authors:  Ivan V Litvinov; Elena Netchiporouk; Brendan Cordeiro; Marc-André Doré; Linda Moreau; Kevin Pehr; Martin Gilbert; Youwen Zhou; Denis Sasseville; Thomas S Kupper
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

Review 3.  SWI/SNF chromatin remodeling complexes and cancer.

Authors:  Jaclyn A Biegel; Tracy M Busse; Bernard E Weissman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-08-28       Impact factor: 3.908

4.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Authors:  Michael K Kiessling; Patrick A Oberholzer; Chandrani Mondal; Maria B Karpova; Marie C Zipser; William M Lin; Michael Girardi; Laura E Macconaill; Sarah M Kehoe; Charlie Hatton; Lars E French; Levi A Garraway; Gernot Polier; Dorothee Süss; Claus-Detlev Klemke; Peter H Krammer; Karsten Gülow; Reinhard Dummer
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

5.  Contribution and clinical relevance of germline variation to the cancer transcriptome.

Authors:  Bernard Pereira; Emma Labrot; Eric Durand; Joshua M Korn; Audrey Kauffmann; Catarina D Campbell
Journal:  BMC Cancer       Date:  2022-06-20       Impact factor: 4.638

6.  High-resolution SNP arrays in mental retardation diagnostics: how much do we gain?

Authors:  Laura Bernardini; Viola Alesi; Sara Loddo; Antonio Novelli; Irene Bottillo; Agatino Battaglia; Maria Cristina Digilio; Giuseppe Zampino; Adam Ertel; Paolo Fortina; Saul Surrey; Bruno Dallapiccola
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

7.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

8.  The Tumor Suppressor BCL7B Functions in the Wnt Signaling Pathway.

Authors:  Tomoko Uehara; Eriko Kage-Nakadai; Sawako Yoshina; Rieko Imae; Shohei Mitani
Journal:  PLoS Genet       Date:  2015-01-08       Impact factor: 5.917

9.  BCL7B is a potential novel diagnosis and prognosis biomarker for sarcomas using bioinformatics analysis.

Authors:  Dinglong Yang; Xiaodong Gu; Chunjiang Li; Junjun Shi; Yujing Chen; Mingjie Dong; Zhiqiang Zhang
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

10.  Altered expression of Bcl-2, c-Myc, H-Ras, K-Ras, and N-Ras does not influence the course of mycosis fungoides.

Authors:  Joanna Maj; Alina Jankowska-Konsur; Ewa Plomer-Niezgoda; Anna Sadakierska-Chudy; Adam Reich
Journal:  Arch Med Sci       Date:  2013-11-05       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.